{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:45:00Z","timestamp":1792147500464,"version":"4.4.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic autoimmune diseases arise from a heterogeneous interplay of genetic, epigenetic, and environmental factors that culminates in loss of tolerance, chronic inflammation, and tissue injury. Among the pathways linking susceptibility to effector disease, CD40\u2013CD40L is a central regulator of antigen presentation, T\u2013B cell collaboration, and germinal centre responses, while also contributing to extrafollicular autoantibody production. In this review, we first introduce the disease-specific rationale for targeting CD40\u2013CD40L interactions, with a particular focus on systemic lupus erythematosus, Sj\u00f6gren\u2019s disease, and rheumatoid arthritis. We then summarize the multifaceted roles of CD40\u2013CD40L signalling across adaptive immunity, innate immune priming, tissue inflammation, and platelet-driven thrombo-inflammation. Finally, we review the therapeutic translation of this pathway, highlighting insights from early trials of anti-CD40\/CD40L antibodies and recent advances in Fc-silent antibody engineering that preserve target binding while minimizing platelet activation. Together, these data support CD40\u2013CD40L blockade as a renewed and promising mechanism-based strategy in systemic autoimmune rheumatic diseases.<\/jats:p>","DOI":"10.1093\/rheumatology\/keag565","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:50:26Z","timestamp":1791546626000},"source":"Crossref","is-referenced-by-count":0,"title":["CD40\u2013CD40L interactions in systemic autoimmune diseases"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Osaka Metropolitan University Department of Clinical Immunology, Graduate School of Medicine, , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Katsushima","sequence":"additional","affiliation":[{"name":"Osaka Metropolitan University Department of Clinical Immunology, Graduate School of Medicine, , Osaka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Mackay","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute Laboratory of B-Lymphocytes in Autoimmunity and Malignancies, , Herston, QLD 4006,","place":["Australia"]},{"name":"University of QLD Medical School, Faculty of Health, Medicine, and Behavioural Sciences, ,","place":["Australia"]},{"name":"University of Melbourne Department of Microbiology and Immunology, Faculty of Medicine, Dentistry and Health Sciences, , Parkville, VIC,","place":["Australia"]},{"name":"Monash University Department of Immunology and Pathology, Faculty of Medicine, Nursing and Health Sciences, , Melbourne VIC,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3204-6068","authenticated-orcid":false,"given":"Chaim","family":"Putterman","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine and Montefiore Medical Center Department of Medicine and Department of Microbiology & Immunology, , Bronx, NY,","place":["USA"]},{"name":"Bar-Ilan University Azrieli Faculty of Medicine, , Zefat,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,16]]},"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag565\/72033146\/keag565.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag565\/72033146\/keag565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:51:05Z","timestamp":1792144265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article\/doi\/10.1093\/rheumatology\/keag565\/8930824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag565","relation":{},"ISSN":["1462-0332"],"issn-type":[{"value":"1462-0332","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"article-number":"keag565"}}